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Abstract 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting from 
defects in insulin secretion, action or both. The complications arising from poorly 
controlled diabetes mellitus are characterized by increased oxidative stress and 
inflammation. Neutrophils are key mediators of innate immunity which primarily protect 
the host from invading pathogens. In diabetes, neutrophils acquire a primed phenotype 
and are responsible for superoxide mediated host tissue damage. Neutrophil NADPH 
oxidase mediates superoxide release and is activated by PKC induced phosphorylation 
of cytosolic subunits like p47phox, p67phox, p40phox and Rac-2 and translocation to their 
membrane components gp91 and p22phox_ PLA2 derived arachidonic acid is required in 
the activation of the assembled NADPH oxidase. There is a gap in the current literature 
regarding the role of PLA2 in NADPH oxidase activation, therefore, we hypothesize that 
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PLA2 is involved in the priming of neutrophils in diabetes. The aim of this study was to 
identify the specific isoform involved in superoxide generation in neutrophils and 
investigate the PLA2 activity in neutrophils from diabetic subjects. Experiments with 
chemical inhibitors revealed that iPLA2, but not cPLA2 was the primary isoform involved 
in superoxide generation in neutrophils. The specificity of BEL, an iPLA2 inhibitor, was 
confirmed by ruling out the involvement of PAP-1, inhibition of p47phox phosphorylation 
and apoptosis. To confirm the findings, from chemical inhibition experiments, 
knockdown experiments for iPLA2 were conducted in HL60-neutrophil like cells. The 
results from these findings showed that knock down of iPLA2 by siRNA resulted in a 30% 
reduction in superoxide generation. Superoxide generation was increased in neutrophils 
from diabetic subjects with poor glycemic control. This process was inhibited by BEL in 
both healthy and diabetic subjects. It was found that the PLA2 activity from membrane 
fractions of neutrophils was calcium independent, suggesting the role of iPLA2 and this 
was increased in diabetic subjects. The iPLA2 expression was increased both at the 
message and protein levels in neutrophils from diabetic subjects. In order to understand 
the mechanism involved behind priming of iPLA2 in diabetes, in vitro hyperglycemia 
experiments were conducted. There was a significant increase in superoxide generation 
in cells cultured with high glucose, RAGE ligand; S1008 and combination of high 
glucose and S 1008. This increase in superoxide generation or a priming effect was 
prevented by BEL, suggesting that iPLA2 mediates the priming event. This dissertation 
unravels the novel role of iPLA2 in superoxide generation from neutrophils and 
demonstrates it's priming effect in diabetes. 
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Introduction 
1. Diabetes Mellitus 
1.1. Diabetes Mellitus- Background 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting from 
defects in insulin secretion, action or both (1 ). There are two types of diabetes mellitus; 
type 1 and 2. Type 1 diabetes accounts only for 5-10% of total diabetics, and is a result 
of cell-mediated autoimmune destruction of the r3-cells of the pancreas (1 ). Type 2 
diabetes accounts for 90-95% of people with diabetes. The specific etiologic factors for 
type 2 diabetes are currently unknown, but obesity of the subjects is an associated factor 
(1 ). Complications of diabetes are the major cause of morbidity and mortality in persons 
with type 1 and type 2 diabetes (2). Epidemiologic evidence suggests that the 
prevalence of diabetes is increasing and without effective preventive measures, the 
prevalence will continue to increase (3). 
1.2. Complications of Diabetes Mellitus 
The hallmark of diabetes is the susceptibility to infections and complications arising as a 
result of micro and macro vascular injuries. Chronic hyperglycemia and its 
accompanying metabolic abnormalities might be at least, in part, responsible for these 
complications (4). Long term complications of diabetes include cardiovascular disease, 
diabetic retinopathy, kidney disease and nervous system damage (5). Subjects with 
1 
diabetes are also at a greater risk for developing periodontal disease and the severity of 
periodontal disease is associated with the duration of diabetes and the presence of 
diabetic complications (6-9). Possible mechanisms of hyperglycemia induced 
complications include aldose reductase pathway (polyol pathway), the advanced 
glycation end products (AGE) theory, generation of reactive oxygen intermediates and 
protein kinase C activation (2). Figure 1 summarizes these different mechanisms. All 
these theories are valid at a certain level to explain the cellular and molecular alterations 
observed in diabetes and share some common pathways. According to the aldose 
reductase theory increased glucose concentrations leads to an increase in levels of 
sorbitol through the enzyme aldose reductase. Increased sorbitol in turn, induces an 
osmotic change and results in vascular damage. Increased aldose reductase leads to a 
reduction in the NAPDH levels resulting in redox imbalances(10) (11). Advanced 
glycation end products (AGE) are the by-products of non-enzymatic glycation and 
oxidation of proteins and lipids. AGE are formed when molecules interact with glucose 
reactive alpha-oxoaldehydes such as glyoxal, methylglyoxal and 3- deoxyglucosone 
(12). This reaction is described by Maillard as "tissue browning theory" in which proteins 
become irreversibly modified by sugars and observed during ageing (13). There are 
many different forms of AGE, but the major protein adduct formed is carboxy-methyl 
lysine (CML) (14). AGE can result in tissue damage by modification of proteins like 
collagen, enhancing cellular signaling through interaction with receptor for AGE (RAGE) 
by activating MAPK and PKC (15) (16). Inhibition of AGE mediated effects can be 
achieved by altering the structure of AGE cross linking or blocking RAGE have been 
successful in reversing diabetic complications (17-19). There is evidence that AGE are 
increased in diabetes (20, 21 ). Protein Kinase C activation results from an increase in 
2 
the levels of diacyclglycerol (DAG), a natural activator of PKC, in diabetes (22). 
Increased glucose levels can result in elevated intracellular glyceraldehyde-3- phosphate 
and enhanced de nova synthesis of DAG (23). PKC activation causes microvascular 
damage by increased oxidant stress, leukocyte adhesion and alterations in the blood 
flow (24) (25) (26). 
Reactive oxygen intermediates are generated from the reducing equivalents in oxidative 
phosphorylation for glucose metabolism and form free radicals. The levels of reactive 
oxygen intermediates are increased in the presence of high glucose and result in tissue 
damage (27). This also results in a concomitant reduction in the nitric oxide levels 
leading to microvascular damage (28). Major sources of ROS generation in vascular 
cells exposed to hyperglycemic conditions include mitochondria and NADPH oxidases 
(29). NADPH oxidases have been identified as primary physiologic producers of 
superoxide in several animal models of vascular disease, including diabetes and 
increased activity of these enzymes in micro and macrovascular tissues of animal 
models and diabetic patients has been documented (29-31 ). Specific upregulation of the 
subunits of NADPH oxidase, including p47phox, nox-4 and p22phox has been demonstrated 
in diabetes within the kidney (32). In addition, the inhibitor of NADPH oxidase, apocynin, 
improves renal function in streptozotocin-induced diabetic rats. Apocynin acts to impede 
the recruitment of the p47phox and p67phox subunits to the NADPH oxidase complex(32). 
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Figure 1. Mechanisms of hyperglycemia mediated induction of oxidative stress. Aldose 
reductase pathway can result in redox imbalances leading to oxidative stress. Hyperglycemia 
pathway can modulate protein structures resulting in AGE formation which activates MAPK 
through RAGE ligation. In addition AGE also increases PKC activity and increases p47phox 
activity. Adapted from Ref (2). 
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1.3. Diabetes and Oxidative Stress 
Oxidative stress is defined as an imbalance in the production of cellular oxidants and 
antioxidants. The oxidants include superoxide (021 hydrogen peroxide (H202) and 
hypochlorous acid (HCIO). The antioxidants include glutathione, vitamin E, ascorbate, 
and enzymes like glutathione peroxidase, superoxide dismutase and catalase. 
Oxidative stress is associated with an increase in oxidants and a concomitant reduction 
in the concentration of antioxidants. This imbalance results in tissue injury and 
dysfunction (33) (34). One of the major risk factors for oxidative tissue injury is diabetes 
induced hyperglycemia. Hyperglycemia can stimulate oxidative stress and activates 
endothelial cells. Activated endothelial cells that release inflammatory cytokines for the 
recruitment of leukocytes are the initial hallmarks of acute inflammation which if left 
uncontrolled can lead to tissue injury (33, 35). 
2. Neutrophils and Inflammation 
2.1. Neutrophil-Mediated Killing through NADPH Oxidase Activation 
The neutrophil is the body's first line of defense against injury or infection and is 
key mediator in both innate and humeral immunity. The capability to kill bacteria also 
carries an inherent capacity for host tissue destruction. The role of neutrophils in injury 
and infection are two-fold in regards to reactive oxygen species generation. The 
neutrophil is a phagocyte which upon ingestion of foreign bodies generates intracellular 
ROS to aid in microbial killing (i.e. a protective phenotype). In addition, neutrophils have 
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the capacity to release extracellular ROS, a pro-inflammatory action which can lead to 
tissue destruction [37-45]. The NADPH oxidase, comprised of membrane [gp91phox 
(where phox stands for phagocyte oxidase), p22phox, and the small G-protein Rap1A] and 
cytosolic (p47phox, p67phox, p40phox, the small G-proteins Rac2 and Cdc42, and the newly 
identified p29 peroxiredoxin) components, has been described and characterized in the 
neutrophil, mainly from studies about CGD (chronic granulomatous disease). The 
membrane-bound subunits gp91 phox and p22phox together form the heterodimeric 
cytochrome bssa- Upon oxidase activation, the cytosolic subunits p47phox, p67phox, and 
p40phox translocate to the plasma membrane and bind with the cytochrome b558 complex 
(36) . Translocation of the cytoplasmic components to the membrane and their 
association with cytochrome b558 renders the complex functional; the cytochrome then 
transfers electrons from NADPH to 0 2 to create 0 2- (superoxide anion) (37) . 
Activation of the oxidase through binding of soluble ligands (i.e., fMLP) to surface 
receptors usually results in 0 2- production lasting less than 5 minutes, whereas receptor-
independent activation (i.e., PMA) causes prolonged generation of the 0 2- until depletion 
of necessary substrates and cofactors (Figure 2). In intact cells, the activated oxidase 
goes through a continuous process of activation and deactivation. The fMLP receptor, a 
G-protein coupled receptor (GPCR) regulates various activities in neutrophils via a PTX-
sensitive G-protein, which includes chemotaxis/chemokinesis, exocytosis 
(degranulation), and multiple signaling pathways including MAPK, lipid kinases, the 
production of second messengers by various phospholipases (e.g., PLC, PLA2, and 
6 
PLO) and the activation of PKC (36). Protein Kinase C (PKC) catalyzes the 
phosphorylation of p47phox after activation by its natural activator sn-1,2-diacylglycerol 
(DAG) or the tumor promoter phorbol 12-myristate 13-acetate (PMA) (38). 
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Figure 2. NADPH oxidase activation in neutrophils . Ligation of G-protein couple receptors by 
fMLP can activate the signaling cascade resulting in activation of PLO, PLC resulting in the 
release of secondary messengers like DAG and IP3 . This results in the activation PKC and 
phosphorylation of cytosolic subunits of NADPH oxidase (p47phox, p67phox, p40phox, Rac-2) and 
their translocation to the membrane. Association of cytosolic subunits with membrane 
components gp91 and p22phox activates the oxidase and results in superoxide generation. 
Alternatively PMA, a synthetic analog of DAG can directly activate PKC by permeating through 
the cell membranes and generates superoxide. NADPH: nicotinamide adenine dinucleotide 
phosphate, G-protein: guanine nucleotide binding proteins, fMLP: formyl methionine leucyl 
phenylalanine, PLO: phospholipase C, PLO: phospholipase D, DAG: diacyclglycerol, IP3 : inositol 
triphosphate , PMA: phorbol 12-myristate 13-acetate 
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2.2. Neutrophil Function and Host Defense 
Neutrophils play a vital role in the protection of the host from invading micro-organisms. 
In the absence of proper neutrophil function such as in leukocyte adhesion deficiency-I 
(LAD-1) where patients lack CD18 and therefore all 132 integrins; their neutrophils can 
neither tightly adhere to endothelium nor exit the circulation in response to infection. 
LAD-1 patients have recurrent skin and mucosal infections, with most patients dying 
before the age of 10 (39). Chronic granulomatous disease (CGD) is another rare 
disease where neutrophil function is defective due to the genetic defects in p47phox, 
p67phox, p22phox and gp91 phox_ CGD patients have deficient 02- production and 
experience ineffective inflammatory reactions to infection, with suppurative lymph nodes 
and frequent granulomas they suffer from repeated bacterial infections by organisms 
that are catalase positive (i.e. able to breakdown their own H20 2) such as 
Staphylococcus aureus and Aspergillus (37). Chediak-Higashi disease is a rare 
autosomal recessive disease affecting neutrophils and all other lysosomal granule-
containing cells in the body. The disease is secondary to mutations in Lyst, a gene 
encoding a cytoplasmic protein involved in lysosomal trafficking (40, 41 ). The 
neutrophils contain giant granules resulting from specific and azurophilic granule fusion. 
Patients have recurrent bacterial infections, neurological disease, partial albinism, 
platelet dysfunction and early death. Another inherited granule disorder characterized 
by recurrent bacterial infection is specific granule deficiency, marked by the absence of 
neutrophil-specific granules and defensins (37) . 
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While neutrophils are essential for host defense, they are also involved in the pathology 
of various chronic inflammatory conditions and ischemia-reperfusion injury (42-45). Host 
tissue damage may occur through various mechanisms like premature activation (or 
priming), extracellular release of microbicidal products during the killing of some 
microbes, removal of infected or damaged host tissue and failure to terminate acute 
inflammatory responses. lschemia-reperfusion injury is associated with an influx of 
neutrophils into the affected tissue and subsequent activation; this may be triggered by 
substances released from damaged host cells or as a consequence of superoxide 
generation through xanthinine oxidase. Superoxide generation also recruits more 
neutrophils to the affected site and ischemia may be sustained by plugging of capillaries 
with aggregates of activated neutrophils (42, 44, 45). Activation of neutrophils by 
immune complexes in synovial fluid contributes to the pathology of rheumatoid arthritis 
(46). Activation of neutrophils is also evident in essential hypertension, Hodgkin's 
disease, inflammatory bowel disease, psoriasis, sarcoidosis and septicemia, where 
priming correlates with high concentrations of TNF-a (42). Neutrophil-mediated tissue 
damage is evident in the periodontium (47). Superoxide generation was shown to be 
elevated in neutrophils from aggressive periodontitis (48). Pre-incubation of neutrophils 
from rapidly progressive periodontitis (RPP) patients with lipopolysaccharide (LPS) 
extracted from Porphyromonas gingivalis was found to prime the neutrophils for 
enhanced fMLP-stimulated superoxide production in a dose-dependent manner (49). 
Also these neutrophils from aggressive periodontitis displayed elevated superoxide 
generation and impaired chemotaxis associated with reduced DAG-a kinase activity and 
expression (50). Thus, the studies suggest that neutrophils in certain conditions present 
as a pro-inflammatory phenotype and contribute to tissue destruction. 
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3. Neutrophils and Diabetes 
3.1. Hyperglycemia Primes Neutrophils for an Increased Oxidant Stress 
Neutrophil function has been shown to be altered in diabetes. One of the major findings 
regarding the neutrophil functional changes in diabetics is the increased extracellular 
superoxide generation (51-55). This is a symptom of a phenomenon known as 
"priming". Priming of neutrophil leads to the pre-activation of the cell without stimulation 
and excessive reaction to the challenge, which results in augmented cell response. In 
neutrophils, priming is characterized by the release of enzymes prematurely and 
excessively. To this end, reactive oxygen species, in particular the NADPH oxidase-
mediated superoxide release is accepted as the defining characteristic of neutrophil 
priming and thus is defined operationally as augmentation of 0 2- generation in response 
to a second, activating stimulus (Figure 3). Chronic hyperglycemia as a result of poorly 
controlled diabetes can prime (preactivate) neutrophils and monocytes resulting in an 
exaggerated inflammatory response and tissue damage. The neutrophil respiratory 
burst seems to be related directly to the glycemic control, increase in protein kinase C, 
and NADPH oxidase activity (55-57). Hyperglycemia can lead to a novel form of 
neutrophil priming, where elevated protein kinase C (PKC) activity results in increased 
phosphorylation of p4 7phox and superoxide anion (0 2-) (55-57). RAGE signaling in 
monocytes has been shown to increase the phosphorylation of pleckstrin, which is an 
important intermediate in the secretion and activation of proinflammatory cytokines like 
TNF-a and IL-1 ~- RAGE signaling and phosphorylation of pleckstrin is critical in the 
proinflammatory cytokine secretion in response to an elevated Advanced Glycated 
11 
Endproducts (AGEs) in diabetes (58). It was shown that p47phox, a key protein, in the 
assembly of NAPDH oxidase prematurely translocates to the membrane and associates 
with p22phox in neutrophils from diabetic subjects. This observation was also seen in 
cells cultured in high glucose and with a RAGE ligand; S 1008. The premature 
translocation of p47phox in hyperglycemia results in an increased superoxide. Some 
studies have also reported a reduction in superoxide generation (59-61) while few 
observed that there was no difference with healthy controls (62, 63). Others have also 
reported reduction in chemotaxis and phagocytosis (51, 62). 
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Figure 3. Hyperglycemia primes neutrophils for an enhanced respiratory burst. Neutrophils 
exposed to high glucose and AGE are primed, when they are exposed to inflammatory cytokines 
or bacterial toxins, they secrete large amounts of superoxide resulting in tissue damage like 
periodontitis . PMN: Polymorphonuclear neutrophils, AGE: advanced glycation endproducts 
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4. Phospholipase A2 and Superoxide Generation in Neutrophils 
In addition to the PKC mediated resulting in the assembly of NADPH oxidase on the 
membrane, PLA2 (Phospholipase A2)-Arachidonic acid (AA) axis is also critical for 
neutrophil signaling and activation of NADPH oxidase. This pathway may even play 
more significant role in highly active cells such as neutrophils during the inflammatory 
process (64-69) . Findings from pioneering studies by Curnutte showed that NADPH 
oxidase can be activated by AA in a cell-free system (70). Results from studies 
suggested that AA release catalyzed by PLA2 is necessary for both the activation and 
the maintenance of 0 2- generation by the NADPH oxidase (71-73). AA is required both 
for the activation of 0 2.- production and the associated H+channel-mediated efflux (74). 
These findings were further underscored by the ability of arachidonate to stimulate the 
oxidase in a concentration-dependent manner but, unlike PMA, was not inhibited by 
staurosporine, a protein kinase inhibitor (75). It was reported that AGE augmentation of 
an activated neutrophil respiratory burst requires AA generation, through which 
neutrophil NADPH oxidase may be up regulated, enhancing reactive oxygen species 
output (76). AA is generated by cPLA2 , which may be stimulated through an AGE-
activated redox-sensitive pathway (76). 
Phospholipase A2 (PLA2) constitutes a superfamily of enzymes that catalyze the 
hydrolysis of the membrane phospholipids sn-2 ester bond, generating a free fatty acid 
and a lysophopholipid (Figure 4). The PLA2 reaction is the primary pathway through 
which AA is liberated from phospholipids and this forms precursor of the eicosanoids, 
which include prostaglandins (PGs) and leukotrienes (L Ts) (77) (Figure 5). In addition to 
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AA, the other reaction product, the 2-lysophospholipid, may also possess biological 
activity on its own or can be used as a precursor for the biosynthesis of other biologically 
active compounds, such as platelet activating factor (PAF) (78) . 
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Figure 4. General structure of membrane phospholipids and the sites of action of 
Phospholipases. PLA2 cleave the sn-2 group to liberate AA. PLC cleaves the glycerol-
phosphate bond generating IP3 and DAG. PLD cleaves the base to liberate PA. PLA: 
Phospholipase A2, PLC: Phospholipase C, PLO: Phospholipase D, IP3: Inositol 3-Phosphate, 
DAG: Diacylglycerol, PA: Phosphatidic acid. 
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Figure 5. The expression and function of PLA2 in neutrophils. PLA2 cleave AA from sn-2 
position of membranous glycerophospholipids. AA is a secondary signal messenger molecule 
and is a substrate for lipid mediators. COX: cyclooxygenase, LO: lipoxygenase, PGE2: 
Prostaglandin E2, L TB4: Leukotriene 84, L~: Lipoxin Pv.. PAF: Platelet activating factor. 
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4.1. Classification of PLA2 
PLA2 consists of 15 groups and many subgroups and includes five distinct types of 
enzymes, namely the secreted PLA2s (sPLA2), the cytosolic PLA2s (cPLA2), the Ca2+ 
independent PLA2s (iPLA2), the platelet-activating factor acetylhydrolases (PAF-AH), 
and the lysosomal PLA2s (79) (Table1 ). 
4.1.1. Secretory PLA2 
The secreted PLA2s (sPLA2) are small and secreted proteins (14-18 kDa) and contain 5-
8 disulfide bonds. These groups of enzymes use an active histidine site and require 
micromolar levels of Ca++ for catalytic activity. The sPLA2s have been named as groups, 
Gl,Gll,Glll,GV,GIX,GX,GXl,GXll,GXlll,GXIV. The sPLA2s have the ability to release AA 
from sn-2 position of phospholipids and its subsequent conversion to eicosanoids (79). 
Neutrophils express GV and GX sPLA2s, wherein, GV sPLA2 is secreted into the 
extracellular medium and GX sPLA2 confined to the plasma membranes (80, 81). GV 
and GX sPLA2s do not seem to contribute much to the AA release and L T84 secretion in 
neutrophils(80) 
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Family Group kDa Source Ca2+ requirement 
sPLA2 18 PA,~ mmol/L 
(Secretory) IIA U/N mmol/L 
IIC T mmol/L 
IID D/I/N mmol/L 
IIE 14-19 u mmol/L 
IIF ME/MT mmol/L 
V Hh/N mmol/L 
X D/I/N mmol/L 
XII H/K/P/S mmol/L 
Ill 55 H/K/US mmol/L 
cPLA2 IVA (a) 85 U/N mmol/L 
IVB (~) 114 8/H/UP mmol/L 
IVC (y) 61 H/S none 
iPLA2 VIA(~) 84-88 U/N none 
VIB (y) 63 and 77 u none 
Table 1. Classification of PLA2. PLA2 can be classified into secretory (sPLA2, calcium 
dependent (cPLA2) and calcium independent (iPLA2). Adapted from Ref (82). 
~. islet ~-cells; B, brain; D, digestive organs; h, human; H, heart; I, immune organs; K, kidney; L, 
liver; ME, mouse embryo; MT, mouse testis; PA, pancreatic acinar cells; S, skeletal muscle; T, 
testis; U, ubiquitous. Membrane-associated, N, Neutrophils 
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4.1.2. Calcium Dependent Cytosolic Phospholipase A2 (cPLA2) 
The Group IV PLA 2 family is comprised of six intracellular enzymes commonly called 
cytosolic or calcium dependent PLA2 (cPLA2) a, cPLA2J3, cPLA2y, cPLA28, cPLA2E and 
cPLA2~- cPLA2 a, the most extensively studied Group IV PLA2, is widely expressed in 
mammalian cells and mediates the production of functionally diverse lipid products in 
response to extracellular stimuli (83) . It has PLA2 and lysophospholipase activities and 
is the only PLA2 that has specificity for phospholipid substrates containing AA. Because 
of its role in initiating agonist induced release of AA for the production of eicosanoids , 
cPLA2a activation is important in regulating normal and pathological processes in a 
variety of tissues (83) . The predominant form of cPLA 2 present in neutrophils is cPLA2a. 
cPLA2 translocates from the cytosol to the nuclear membrane and endoplasmic 
reticulum (ER) by agonists which increase cytoplasmic [Ca2+] in a variety of cells (Figure 
6). It has also been shown that the cPLArC2 domain (calcium binding domain) has 
specificity to the phosphatidylcholine-rich nuclear envelope and ER and aromatic and 
hydrophobic residues in the calcium-binding loop of the cPLArC2 domain are important 
for its lipid specificity (84). The role of cPLA 2a in superoxide generation was examined 
in human neutrophils via specific inhibitor pyrrolidine-1 and in cPLA 2a knock out mice 
neutrophils. Evidence in the literature suggests that while inhibiting cPLA2a led to a 
completely suppression of AA release, there was no effect on NADPH oxidase activation 
(85). 
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Figure 6. cPLA2 activation in neutrophils is receptor and calcium mediated . Ligation of 
receptor (TLR, G-Protein , etc) with ligands like fMLP, LPS, TNF-a , results in the phosphorylation 
of ERK 1 /2 and PLC activation and increase in calcium levels. Phosphorylation and calcium 
activate cPLA2 to translocate on nuclear and ER membranes. 
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4.1.3. Calcium Independent Phospholipase A2 (iPLA2) 
GVI Ca2+ independent PLA2s (iPLA2s) do not require Ca2+ for the activity. They are 
further classified into two groups iPLA2 VI-A (r3), iPLA2 Vl-8 (y). iPLA2 VI-A is involved in 
regulating homeostatic phospholipid levels via fatty acid deacylation/reacylation 
reactions. Although iPLA2 VI-A bears no sequence homology with cPLA2a, both 
enzymes share some common biochemical features such as cytosol location in resting 
cells, a molecular mass in 85kDa range, and the existence of a catalytic serine. 
However unlike cPLA2a, iPLA2 VI-A does not demonstrate substrate specificity for AA at 
sn-2 position in phospholipids. iPLA2 VI-A occurs in at least 5 different splicing variants 
(78, 86). Two of them have been demonstrated to possess enzymatic activity and are 
termed VIA-1 and VIA-2. iPLA2 VI-A-1 is an 85 kDa enzyme that possesses eight 
ankyrin-like repeated domains in the N-terminal half of the protein followed by a classical 
GXSXG lipase consensus motif that Ser465 as the catalytic nucleophile in the active site. 
iPLA2 VI-A-2 is similar to iPLA2 VI-A-1 except for the fact that the eighth ankyrin domain 
is interrupted by a praline rich 54 rich amino acid stretch. Two of the iPLA2 variants 
possess only the ankyrin repeated domains and thus enzymatic activity (Figure 7). 
These proteins have been suggested to act as dominant negative inhibitors for the active 
variants. The fifth iPLA2 VI-A splicing variant, termed iPLArVIA-3 is identical to iPLA2 
VI-A-2 but exhibits a truncated C-terminus as a consequence of a premature stop codon 
due to the insertion of a 158-nucleotide stretch (78). In addition to its intrinsic PLA2 
activity, iPLA2 VI-A also exhibits lysophospholipase and phospholipid transacylase 
activities (87) (Figure 8). 
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Schematic representation of the multiple iPLArVIA splicing variants. 
iPLA2 exists as a multiple splicing variants. The presence of eight ankyrin repeated domains 
account for the enzymatic activity. Adopted from Ref [66]. 
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Figure 8. iPLA2 signaling . iPLA2 is a membrane bound enzyme that is active in the presence of 
calcium. Depletion of calcium liberates calmodulin and iPLA2 is activated. Activated iPLA2 
liberates AA, lyso-PAF and also remodels AA back into the membranes by reacylation pathway. 
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4.2. Regulation of iPLA2 Activity 
There is a gap in current knowledge as to how cells regulate iPLA2 activity. Studies 
have shown significant basal iPLA2 activity as seen by the decrease in the steady state 
level of cellular lysoPC after inhibition (88). Because of the co-existence of various 
iPLA2 splice variants, there can be many regulatory mechanisms dictated by different 
cell types and stimuli (78, 88, 89). In the presence of Ca2+, calmodulin binds tightly to 
iPLArVIA resulting in inhibition of the enzymatic activity. In the absence of Ca2+, 
calmodulin would separate from and relieve its tonic inhibition of iPLA2 (90). A 15 kOa 
region near the C-terminus of the Group VIA (around residues 694-705) has been 
identified to participate in the Ca2+ -dependent binding of calmodulin to iPLArVIA (90). 
Although this C-terminal region of iPLA2 appears to constitute the major calmodulin-
binding site, the possibility that other binding sites exist within the iPLArVIA sequence 
has not been ruled out (78). Until now, no phosphorylation site has been identified to 
exist in iPLA2. There have been suggestions that a kinase acts as a co-factor for iPLA2 
activity, similar to that described for PKC regulated PLO (91 ). It has been suggested 
that PKC can directly activate PLO without phosphorylation it or interact with another 
protein which in turn will activate PLO (91 ). iPLArVIA can be immunoprecipitated by a 
specific anti-phosphoserine antibody in a protein kinase C-dependent manner, in 
interferon y-primed U937 monocytes stimulated through cross-linking of Fey-RI (92). 
Protein kinase C regulation of iPLArVIA has also been reported in zymosan-stimulated 
P388O1 macrophages, where the E-isoform of the kinase is suggested to regulate the 
translocation of iPLArVIA to membrane fractions (93). Similar to these findings, the E-
isoform of protein kinase C has been reported to mediate the increased association of 
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iPLA2 activity to membrane fractions (94). Thrombin-stimulated vascular smooth muscle 
cells have provided evidence for the involvement of p38 MAPK in the cellular regulation 
of iPLArVIA. iPLArVIA was also involved in fatty acid release and DNA synthesis, and 
these actions are blocked by inhibitors of p38 MAPK. Thrombin was found to increase 
the iPLA2 specific activity of cell extracts, and such an increase is blocked if the extracts 
are prepared from cells pretreated with MAPK inhibitors (95). iPLA2 is characterized by 
presence of seven or eight ankyrin-like repeated domains in the N-terminal half of the 
protein (eight in the VIA-1 variant, and seven in the VIA-2 variant). These ankyrin 
repeats are present in vast number of proteins, and have been implicated in facilitating 
protein-protein interactions (96). Furthermore, deletion of the ankyrin repeats by 
removing the first 150 amino acids yields an inactive iPLArVIA (97). Thus it appears 
likely that the ankyrin repeats enable oligomerization of the enzyme and hence 
expression of full enzymatic activity (78). Since many cells express truncated iPLA2 
protein fragments containing the ankyrin repeats but lacking activity, it has been 
suggested that these inactive fragments might function as regulators of iPLArVIA by 
interfering with the ankyrin-mediated oligomerization of the active fragments (78, 98, 99). 
4.3. Functions of iPLA2 
Studies indicate that alterations in the activity and/or expression of iPLArVIA exert 
profound effects on phospholipid metabolism that affect cell growth (78, 100-102). 
Eicosanoids are a family of bioactive compounds that derive from the enzymatic 
oxygenation of AA. The key role of eicosanoids in pathophysiology is related to their 
actions in inflammation (78, 103). Studies in phagocytic cells, which are cells typically 
involved in inflammatory reactions, have generally shown that the selective AA 
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mobilization response and ensuing eicosanoid metabolism triggered by both receptor-
directed and soluble agonists is insensitive to BEL (specific iPLA2 inhibitor), which rules 
out a role for iPLArVIA in the process (104-107). It was show that iPLA2 regulates AA 
release and eicosanoid generation(108). BEL has been shown to strongly blunt AA 
mobilization in nitric-oxide-treated RAW261.7 macrophages (108) calcium-ionophore 
stimulated neutrophils (109), suggesting the involvement of a BEL-sensitive iPLA2. In 
phagocytic cells iPLArVIA inhibition by either BEL or antisense reduces AA mobilization 
and prostaglandin production in zymosan-stimulated P388D1 macrophages (uncloned 
ATCC cells) (110), and in interferon-y-primed U937 cells stimulated via cross-linking of 
FcyRI (92). iPLA2 does not possess a preferential activity for AA at the sn-2 position in 
the phospholipids, the enzyme is able to hydrolyze any fatty acid (97). iPLA2 activation 
results in the release of free fatty acids along with AA (95, 111, 112). iPLA2 is activated 
in conditions where there is depletion of calcium free conditions (90) (113), but in iPLAr 
VIA-transfected HEK293 cells, calcium-ionophore-induced AA release is greatly 
increased, and the resultant fatty acid is converted to prostaglandins preferentially via 
cyclooxygenase-1 (114, 115). Increased fatty acid release and prostaglandin production 
in response to calcium ionophore in iPLArVIA-transfected cells is a very striking result, 
and suggests that under some conditions, the enzyme might be regulated by Ca2+ 
dependent factors (78). Hence, these studies show that iPLA2 regulates eicosanoid 
metabolism by the release of AA which contributes to cell signaling. 
iPLA2 is also involved in cellular apoptosis. It was shown that iPLA2 cleavage by 
caspase-3 resulted in the loss of N-terminal and subsequent activation leading to 
membrane phospholipid destruction (111, 116, 117). Importantly however, inhibition of 
iPLArVIA activity by either MAFP or an antisense oligonucleotide did not prevent 
27 
apoptosis, suggesting that although iPLArVIA does participate in membrane 
phospholipid destruction during apoptosis, it is not absolutely required for the apoptotic 
process to fully develop (78, 117). Evidence for iPLA2 involvement in generating signals 
for the optimal clearance of apoptotic cells by phagocytes, the so-called "eat me" 
signals, has also been provided (118). Exposure of iPLArderived lysoPC on the surface 
of apoptotic T cells is thought to facilitate binding of lgM and complement factors, 
leading to their eventual recognition and clearance by phagocytes (118). iPLA2 plays a 
role in calcium signaling and it was suggested that depletion of intracellular Ca2+ stores 
results in an increased iPLArmediated phospholipid hydrolysis and accumulation of free 
fatty acids including AA in rat smooth muscle cells and pancreatic islets (119, 120). One 
study demonstrated that in Ca2+ depleted neutrophils stimulated with agonists, 
arachidonic acid release and L TB4 synthesis correlated with extracellular Ca2+ influx 
(121 ). iPLA2 is required in the activation of store-operated calcium channels and Ca2+ 
influx in a variety of cell types, including vascular smooth muscle cells, Jurkat T-
lymphocytes, platelets and rat basophilic leukemia cells. It was demonstrated that the 
production of calcium-influx factor subsequent to intracellular Ca2+ store depletion would 
act to displace calmodulin from iPLA2, leading to its activation and the production of 
lysophospholipids, which activates the store-operated channels and Ca2+ influx. Upon 
refilling of the stores and cessation of calcium-influx factor production, calmodulin would 
reassociate with iPLArVIA, thereby inhibiting it. This would terminate the activity of 
store-operated channels and capacitative calcium influx (113, 122). Thus, intracellular 
calcium levels regulate iPLA2 activity and calcium influx in turn is regulated by iPLA2 
activity. Evidence from the literature suggests that AA is required for the activation of 
NAPDH oxidase and the generation of superoxide. cPLA2 is the primary PLA2 isoform 
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which regulates the release of AA from membrane phospholipids due to specific sn-2 
position activity. However, in cPLA2 null mice model, it was shown that superoxide 
generation was not inhibited (85) even though there was a completion suppression of AA 
release. iPLA2 has also shown to be associated with AA mobilization, hence it would be 
interesting to examine the role of iPLA2 in superoxide generation. iPLA2 is also involved 
in the superoxide generation from neutrophils stimulated with Aroclor 1242, an 
organochloride compound. In this study, BEL blocked superoxide generation and AA 
release induced by Aroclor 1242 from neutrophils (123). But, conclusions cannot be 
drawn from this study because there was no selective inhibition of iPLA2 and the 
stimulus was pharmacological and not physiological. It is also not known how Aroclor 
1242 induces iPLA2 activation. 
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Hypothesis 
Based on the evidence from literature review, we hypothesize that "PLA2 is involved in 
the priming of neutrophils in superoxide generation from diabetic subjects". iPLA2 
activation of superoxide generation in neutrophils might characterize a novel pathway of 
NADPH oxidase activation and lead to a better understanding of the priming in diabetes. 
Aims 
1. Characterize the PLA2 isoforms involved in the generation of superoxide in 
neutrophils. 
2. Determine the PLA2 expression and activity of neutrophils from diabetic subjects. 
3. Investigate hyperglycemia related PLA2 activity in neutrophils in vitro. 
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Methods 
Reagents 
N-formyl-Methionyl-Leucyl-Phe, S100B protein, cytochrome C and propranolol 
hydrochloride were purchased from Sigma (St.Louis, MO). A23187, pyrrolidine-1 and 
BEL were purchased from EMO-Biosciences (San Diego, CA). L TB4 ELISA kit was from 
R&D systems (Minneapolis, MN). Arachidonic acid, iPLA2 polyclonal antiserum, and 
cPLA2 assay kit were purchased from Cayman Chemicals (Ann Arbor, Ml). HL60 cells, 
RPMI medium and lscove's medium were obtained from American Type Cell Culture 
(Manassas, VA). Trizol reagent was from lnvitrogen Corporation (Carlsbad, CA). High 
capacity cDNA reverse transcriptase kit, real time probes for 13-actin, iPLA2 and master 
mix were from Applied Biosystems (Foster City, CA). Amaxa Nucleofector V solution 
and human monocyte Nucleofector medium were from Amaxa Incorporation, 
(Gaithersburg, MD). siRNA for GAPDH, non-targeting and iPLA2 were from Dharmacon 
RNAi technologies (Lafayette, CO). Antibody for p47phox was from BO Biosciences (San 
Jose, CA) and PKC phospho substrate was from Cell Signaling Technology Inc 
(Danvers, MA). 
Subject Recruitment 
Sixty five diabetic and systemically healthy individuals have been recruited at the Clinical 
Research Center of Boston University Goldman School of Dental Medicine. 
Systemically healthy served as the control and were age, gender, and race matched 
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normoglycemic individuals with no systemic or local infections (e.g., periodontitis). All 
subjects signed an informed consent and the study was approved by the Boston 
University Institutional Review Board. Patients with diabetes mellitus (OM) were selected 
according to the criteria of the American Diabetes Association(124) . Demographic data 
for the diabetic patients including type of diabetes, age, gender, and race were recorded 
(Table 2). The glycemic control of diabetes was assessed by glycated hemoglobin 
(HbA 1 c %). We have chosen to subgroup the diabetic subjects into poor glycemic 
control and good glycemic control, since it was previously shown that poor glycemic 
control (HbA1c :2: 8%) or good glycemic control (HbA1c ~ 7%) (55). 
Neutrophil Isolation 
Peripheral venous blood was collected into heparinized tubes. Neutrophils were isolated 
using a discontinuous gradient system (55). Briefly, peripheral blood was layered on a 
mixture of MonoPoly (Flow Laboratories, McLean, VA), Histopaque 1119, and 
Histopaque 1077 (Sigma, St. Louis, MO), and the tubes were centrifuged at 500g for 30 
min. The neutrophil-rich layer was collected and contaminating erythrocytes were lysed 
with a hypotonic NH4CI buffer (155 mM NH4CI, 10 mM KHCO3, 120 µM EDTA, pH 7.4). 
Cells were washed twice with phosphate buffered saline (PBS; 13.3 mM Na2HPO4, 6. 7 
mM KH2PO4, pH 7.2, 0.15 M NaCl), resuspended in 50 ml PBS, and counted with a 
Neubauer hemocytometer. Cell preparations were routinely 99% neutrophils with ~ 95% 
viability, as determined by trypan blue exclusion. 
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Healthy Diabetes 
n 65 65 
Age (Mean in yrs) 37.7 ± 9.98 55. ± 10.83 
Gender Male 38 38 
Female 27 27 
Ethnicity African-American 15 35 
Caucasian 39 24 
Asian 6 2 
Hispanic 5 4 
Smoking status Non-smokers 55 29 
Former-Smokers 8 15 
Smokers 2 15 
Type of Diabetes Type 1 8 
Type2 57 
Mean Hb1Ac % 7.94 ± 1.8 
Glycemic Control Poorly controlled subjects 18 
(based on Hb1Ac %) (>8% Hb1Ac) 
Moderately controlled ( 7- 8% 17 
Hb1Ac) 
Well controlled subjects (<7% 20 
HbA1c) 
Duration of diabetes 7.13±6.9 
(Mean in yrs) 
Periodontal Healthy 16 
condition 
Mild 17 
Moderate 9 
Severe 20 
Table 2. Demographic data of healthy and diabetic subjects (mean ±SD). There were no 
significant differences between the age groups. 
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Human Pro-Myelocytic Leukemic Cells (HL60) as a Model for Neutrophils 
Since neutrophils are terminally differentiated cells, have short lifespan, and therefore 
cannot be used for long-term incubations, for experiments that require testing the 
chronic exposure to hyperglycemic conditions and transfection, we have used human 
pro-myelocytic leukemic cell line HL60 cells and differentiated them into neutrophil-like 
cells (125). Studies have previously demonstrated the expression of PLA2 in both 
undifferentiated and neutrophil-like HL60 cells (126-128). In order to assess the validity 
of differentiated HL60 cells as a model to study the neutrophil biology, we have tested 
the functional similarities as well as expression levels of key molecules in signaling in 
both cells. HL60 cells (ATCC) were cultured in lscove's medium supplemented with 
10% heat inactivated fetal bovine serum (HIFBS) at 37°C in a 5% CO2 atmosphere until 
confluent. The final concentration of cells in the medium was 0.5 x 106 cells/ ml. To 
initiate differentiation, 50 x 106 cells were centrifuged (1 00xg) and transferred to new 
flasks containing 50 ml of pre-warmed RPMI medium supplemented with 10% HIFBS, 
glucose (5.5 mM) and 1.25% dimethyl-sulfoxide (DMSO). On the third day, cells 
received an additional 10ml of media supplemented with glucose (5.5 mM), DMSO 
(1.25%) and 10% HIFBS (129). The cells were counted on the 6th day and cell viability 
was evaluated using trypan blue exclusion . Superoxide assay was performed to confirm 
the differentiation process into neutrophil-like cells. In order to simulate the 
hyperglycemic conditions as a model for diabetes-induced hyperglycemia, differentiated 
HL60 cells (1 x1Q6 /ml}, upon differentiation, were incubated in RPMI culture medium (-
glucose, + glutamine), 10% HIFBS at 37° C, 5% CO2 atmosphere for a period of 24 
hours under the following conditions; normal glucose (NG, 5.5 mM), high glucose (HG, 
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25 mM), S1008 (5 µg/ml), S1008 + HG. After the indicated periods, cells were counted 
using trypan blue exclusion and the cell number was adjusted accordingly for further 
experiments. 
Superoxide Release Assay 
Superoxide (0 2-) release was monitored spectrophotometrically at 37°C by measuring 
superoxide dismutase-inhibitable reduction of ferricytochrome C at 550 nm (55). Assays 
were carried out in 96-well microtiter plates with flat-bottomed wells (Linbrotype, Flow 
Laboratories). Five separate samples were used for each condition. Control wells 
contained all of the components of the assay mixture plus superoxide dismutase (20 
U/ml) to correct for ferricytochrome C reduction by agents other than 02-. Cells (0.5 x 
105) were suspended in PBS (200 µI/well) and stimulated by the addition of fMLP (1 µM) 
and the absorbance (optical density) at 550 nm, recorded in a Vmax kinetic microplate 
reader (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, USA) at 550 nm and 
37°C). 0 2- release was measured under conditions of linearity with respect to time and 
cell number and is expressed as nmole 0 2-min/10 5 neutrophils (55). For chemical 
inhibition experiments, neutrophils (25 x 106/ml) were incubated with specific inhibitors 
for 15 minutes in pre-warmed PBS in a shaking water bath at 37 °C. Control neutrophils 
received equivalent volume of the diluent. Cell viability was assessed for all 
concentrations of the inhibitors by trypan blue exclusion . 
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Leukotriene 84 (LT84) Secretion 
The secretion of L TB4 into the extra cellular medium was assessed by parameter 
competitive immunoassay ELISA for L TB4 from R&D Systems (Minneapolis, MN) 
according to the instructions by the manufacturer. Neutrophils (1 Ox 106/ ml) were 
suspended in pre-warmed PBS containing 0.25% bovine serum albumin (BSA) and 1 
mM CaCl2. Cells were then stimulated with varying agonists for varying periods of time. 
Controls cells received equal volume of the diluent. The cells were then centrifuged at 
2,000xg for 15 minutes at 4°C. The supernatant was collected and stored at -80°C until 
assay. This assay is based on the forward sequential competitive binding in which L TB4 
present in a sample competes with a fixed amount of horseradish peroxidase (HRP) -
labeled L TB4 for sites on a chicken polyclonal antibody. During incubations, the chicken 
polyclonal antibody becomes bound to the rabbit anti-chicken antibody coated onto the 
microplate. Following a wash to remove excess conjugate and unbound sample, a 
substrate solution is added to the wells to determine the bound enzyme activity. 
Immediately following color development, the absorbance is read at 450nm in a 
spectrophotometer . The intensity of the color is inversely proportional to the 
concentration of L TB4. 
Quantitative Real Time PCR 
Total RNA was extracted from neutrophils or HL60 neutrophil like cells by Trizol reagent 
(lnvitrogen) as per the manufacturer's protocol. Cells (5-10 x 106) were homogenized in 
1 ml of Trizol reagent by repetitive pipetting. The samples were then incubated at room 
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temperature for 5 minutes to permit the complete dissociation of nucleoprotein 
complexes. Chloroform (200µ1) was added to Trizol and the tubes were shaken 
vigorously for 15 seconds and incubated at room temperature for 2-3 minutes. The 
samples were then centrifuged at 12,000xg for 15 minutes at 4°C. Following 
centrifugation, the mixture separates into lower red, phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains exclusively in the 
aqueous phase. The upper aqueous phase was carefully transferred without disturbing 
the interphase into fresh tube. The RNA was precipitated from the aqueous phase by 
mixing with 0.5 ml isopropyl alcohol per 1 ml of TRIZOL Reagent used for the initial 
0 
homogenization. The samples were incubated at 15 to 30 C for 10 minutes and 
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centrifuged at 12,000xg for 10 minutes at 2 to 4 C. The RNA precipitate, often invisible 
before centrifugation, forms a gel-like pellet on the side and bottom of the tube. The 
RNA pellet was washed once with 75% ethanol, adding at least 1 ml of 75% ethanol per 
1 ml of TRIZOL Reagent used for the initial homogenization. The samples were mixed 
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by vortexing and centrifuged at 7,500xg for 5 minutes at 2 to 8 C. All the left over 
ethanol was removed and the RNA pellet was air dried for 5-10 minutes. The RNA pellet 
was dissolved in DEPC-treated water by passing solution a few times through a pipette 
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tip. The samples were then incubated at 55 C for 10 minutes. The concentration and 
purity of the RNA was estimated by the A2sofA2ao ratio on a spectrophotometer 
(Nanodrop, Thermo Fischer Scientific). The A260/A280 ratio was routinely above 1.6. 
High capacity cDNA reverse transcriptase kit (Applied Biosystems) was used for the 
preparation of cDNA from RNA. One µg of RNA was added in a 50µ1 of the reaction 
mixture consisting of RT buffer, random primers, DTNPs, reverse transcriptase enzyme 
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supplemented with RNase inhibitor and RNase free water. The reaction mixtures were 
thoroughly mixed and subjected to 25°C for 10 minutes, 37°C for 120 minutes and 85°C 
for 0.05 minutes in a thermal cycler (ABI 9700, Applied Biosystems, Foster City, CA, 
USA). Real-time PCR was performed using primers and TaqMan probes for GAPDH 
and iPLA2 (Group VI) labeled with FAM dye (Applied Biosystems, TaqMan® gene 
expression assays). Beta-actin was selected as an endogenous control and amplified 
using pre-formulated VIC-TAMRA labeled TaqMan probes (Applied Biosystems, 
Endogenous Control). Quantification was performed in an automated thermal cycler 
(ABI Prism 7000 Sequence Detector, Applied Biosystems, Foster City, CA, USA). The 
reaction mixtures were subjected to 50°C for 2 minutes (1 cycle), 95°C for 10 minutes (1 
cycle), 95°C for 15 seconds (45 cycles) and finally 60°C for 1 minute. The results 
analyzed through a software interface and Excel spreadsheet for the calculation of 
relative expression (GAPDH/f3-Actin or iPLA2/f3-Actin). 
iPLA2 Activity Assay 
cPLA2 assay kit was obtained from Cayman chemicals (Ann Arbor, Ml). The assay is 
based on the principle that the hydrolysis of Arachidonoyl thioester bond at the sn-2 
position by PLA2 releases free thiol which is detected by 5,5'-Dithio-bis(2-nitrobenzoic 
acid) (DTNB) (Figure 9). The assay detects calcium dependent PLA2s. Cell preparation 
was performed according to the manufacturer's protocols. Neutrophils 4x108/ml were 
lysed in cold buffer consisting of 50 mM HEPES pH-7.4, containing and 1 mM EDT A. 
The cells were then sonicated in ice-cold water in two bursts of 15 seconds each at 1.5 
amplitude at a setting of 30 mA. The lysate was then spun at 600xg for 5 minutes at 
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4°C. The pellet consists of unbroken cells and debris and is discarded. The supernatant 
is considered as a whole cell fraction and was further centrifuged at 11,000xg for 30 
minutes at 4°C. The resulting pellet was membrane rich fraction and the supernatant 
was cytosol rich fraction . The membrane rich fraction was confirmed by western blotting 
for Na+'K+ ATPase, which is specific for cytoplasmic membrane (130, 131). The protein 
concentration from each fractfon was performed by Bradford 's protein assay. To 
2+ 
determine the activity of iPLA2 , a modified Ca free assay buffer of the following 
composition was prepared ;300 mM NaCl, 60% glycerol, 10 mM HEPES, 8 mM Triton X-
100, 4 mM EGTA, and 2 mg/ml of BSA (pH 7.4) (132) (Figure 9). Ten microliters of the 
sample was incubated in modified IPLA2 buffer and Arachidonyl Thio-Phosphatidyl 
Choline for 60 minutes in a 96 well plate. The reaction was stopped by the addition of 
10 µI DTNB/EGTA and the colorimetric reaction was read at 414 nm in a plate reader. 
PLA2 activity was calculated as shown in Figure 10. 
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iPLA2 ASSAY 
Arachidonyl Thio-PC 
~ ~~;";' l C: iPLA 2 (sample) 
AA 
Free thiol group 
l DTNB 
5-Thjo-2-Nitrobenzoic acid 
/,.,max: 412nM 
Figure 9. iPLA2 activity assay. Neutrophils (4 x 108 / ml) were rapidly lysed in buffer consisting 
of 1mM EDTA and 50Mm HEPES and sonicated. Membrane fractions were isolated and added to 
Arachidonyl Thio-PC in the absence or presence of Calcium and /or EDTA. The samples were 
incubated for 60 minutes in a 96 well plate and the reactions were stopped by the addition of 
DTNB/EGTA. The colorimetric change was read at 414nm. 
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A41Jmin = ,¾14 (sample)- A414 (Blank) 
PLA.i activity = A4,Jmin 
10.66mM1 
60 minutes 
0.225 ml 
x x sample dilution= µmol/ml/min 
0.01 ml 
Figure 10. Calculation of iPLA2 activity. Optical density was recorded at 414 nm in a plate 
reader. 10.66 mM-1 = DTNB extinction coefficient adjusted for path length. 0.225 ml = Total 
volume of reaction mixture in each well. 0.01 ml = Volume of the sample 
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Cell Fractionation 
Neutrophils (25 x 10 6 / ml) were lysed in ice-cold extraction buffer [20 mM Tris-HCI (pH 
7.4), 10 mM HEPES, 25 mM NaCl, 2 mM EOTA, 10 mM EGTA, 1 % (w/w) protease 
inhibitor cocktail]. The cells were then ultrasonicated 5 times at 30W for 5 seconds. 
This fraction of cell lysates was considered as whole cell lysates. For further 
fractionation whole cell lysates were centrifuged at 1000xg for 5 minutes at 4° C. The 
resulting pellet was then discarded and the supernatant was further centrifuged at 
11,000xg for 30 minutes. The supernatant resulting from this procedure is cytosolic 
fraction and the pellet is the membrane fraction. The pellet was suspended in ice-cold 
extraction buffer with 0.5 % Triton X-100 and 1 mM PMSF by ultrasonication 5 times at 
30 W for 5 sec, and incubated for 20 min at 4 °C. Protein content in each fractionate 
was then estimated using Bradford assay. The authenticity of the cell fractionates were 
verified by using plasma membrane marker Na+/K+ ATPase antibody. In experiments 
where cells were stimulated with fMLP, the reactions were stopped by ice-cold extraction 
buffer and the fractions were prepared as described above. 
Western Blotting 
The protein samples for western blotting were prepared as described in the literature 
(54). Neutrophils or HL-60 cells were lysed (total or cell fractionates) by adding 40µ1 of 6 
x SOS sample buffer to 200 µI of the reaction mixture and then boiling the samples for 5 
minutes. The final composition of SOS sample buffer after mixing was 2 % (w/v) SOS, 
58.3 mM Tris-HC1 (pH 6.8), 6 % (v/v) glycerol, 5 % (v/v) 2-mercaptoethanol, 0.002 % 
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(w/v) bromophenol blue, 1 % (v/v) protease inhibitor cocktail and 1 mM PMSF. Aliquots 
of these samples were separated by SOS-PAGE (10-20µg/lane) on 7.5% or 10 % (v/v) 
polyacrylamide slab gels. The separated proteins were immediately transferred 
electrophoretically to PVOF membranes utilizing TB buffer [25 mM Tris, 192 mM glycine 
and 20 % (v/v) methanol; pH 8.4]. Proteins were transferred at 100 V for 1 hour at 4 °C. 
Membranes were blocked for 1 hour at room temperature with 5 % skim milk in Tris-
buffered saline (pH 7.6) (TBS). The blocking buffer was removed, and the membranes 
were incubated with the appropriate primary antibodies (1 :500 dilution for p47phox, 1 :1000 
in 3% skim milk for iPLA2, 1: 1000 for cPLA2 and 1 :500 for Phospho PKC substrates) 
overnight at 4 °C in 20 mM Tris-HCI (pH 7.6) containing 250 mM NaCl, 0.1 % (v/v) 
Tween 20, 1 % (w/v) BSA and 0.002 % (w/v) NaN3. The membranes were 
subsequently washed 3 x times in TBST [20 mM Tris-HC1 (pH 7.6) containing 150 mM 
NaCl and 0.1 % (v/v) Tween 20] and then incubated with the secondary antibodies (goat 
anti-mouse or rabbit lgG-HRP conjugate; 1 :5000 dilution) in TBST for 1 hour at room 
temperature. Membranes were washed three times in TBST. The activity of HRP was 
visualized by incubating the membranes for 5 minutes at room temperature in an ECL 
detection system (Pierce) followed by autoradiography. At the end of these 
experiments, both the immunodetection system and the bound antibody were removed 
from the blot by incubating the membrane with reprobing buffer [62.5 mM Tris-HCI (pH 
6. 7), 2 % SOS, 100 mM 2-mercaptoethanol] for 30 min at 56 °C followed by 3x times 
washing in TBST. The blots were then stained with an anti-actin antibody (1 :2000 
dilution) to confirm that equal amounts of protein were present in each lane of the gel. 
The band density was measured using an imaging densitometer (Bio-Rad) and 
normalized to the actin band. 
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siRNA Transfection 
HL60 cells (1 x1Q 6/ml) were differentiated for 3 days in RPMl-1640 medium 
supplemented with 1.25% DMSO, 5.5mM D-glucose and 10% HIFBS. On day 3 cells 
(4x 106) were resuspended in 100µ1 of nucleofector solution in Amaxa certified cuvettes 
(Figure 11A). The cells received 1 µM Green Fluorescent Protein (GFP) si- non-
targeting, si-GAPDH or si-iPLA2. The cuvettes were then transferred to Amaxa 
Nucleofector device (Amaxa Inc, Gaithersburg, MD). Electroporation was set at S-11 
program as per the manufacturer's recommendations. The device utilizes 
electroporation method to create micropores in the cytoplasmic membranes of the cells 
and facilitates the entry of siRNA into the cytoplasm. After the transfection cells were 
resuspended in pre-warmed Human Monocyte Nucleofector medium (Amaxa Inc, 
Gaithersburg, MD) at a concentration of (1x106/ml). Cells transfected with GFP were 
analyzed in a fluorescent microscope 24 and 48 hours post transfection to establish the 
transfection efficiency (Figure 118). 
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Figure 11. Transfection of siRNA in HL60 cells. A.) Cells (1 x 106 / ml) were differentiated with 
1.25% DMSO in RPMl-1640 medium supplemented with 5.SmM D-glucose and 10% HIFBS. On 
day 3 cells were transfected using a nucleofector device with siRNA and cultured for 3 days in 
human monocyte nucleofector medium supplement with 1.25% DMSO and 10% HIFBS. Cells 
were counted and samples were collected. B.) Cells were transfected with 1 µM GFP and 
examined in a fluorescent microscope and transfection efficiency was calculated. 
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Cells were counted after 3 days (72 hours post-transfection) using a hemocytometer 
utilizing trypan blue exclusion method. Total RNA was extracted using Trizol ®reagent 
and whole cell lysates were collected for western blotting experiments. Superoxide 
generation was evaluation for si-non targeting and si-iPLA2 transfected neutrophils. 
Fluorescent Activated Cell Sorter (FACS) 
BEL (1, 5, 10, 15 and 20µM), Staurosporine (1 µM) and / or vehicle (0.1 % DMSO and 
PBS) were added to neutrophils (1 x 106 / ml) for 15 minutes at 37 °C. Incubations were 
stopped on ice and neutrophils were immediately spun at 1 OOxg for 10 minutes. 
Supernatant was removed and PMN were resuspended in FACS buffer (PBS with 5% 
FBS) containing FITC-Annexin V (1 :50) and PE-CD16 (1 :200) or Pl to label apoptotic 
neutrophils. Apoptotic neutrophils were characterized by double positive staining for 
Annexin V and Pl assessed by Cell Quest software. 
Statistical Analysis 
All data presented represent the average of at least three experiments with their 
standard error of mean unless otherwise stated. For comparison between two groups 
student's t test was applied for significance and for multiple groups analysis one way 
ANOVA (Analysis of variances) was used with post-hoc Bonferroni or LSD (least 
significance differences) corrections. 
46 
Results 
iPLA2 is Involved in Superoxide Generation in Neutrophils 
Specific chemical inhibitors (BEL; iPLA2 inhibitor, pyrrolidine; cPLA2 inhibitor) were used 
to investigate the role of specific PLA2 isoform in the generation of superoxide in 
neutrophils. Neutrophils were pre-incubated with the inhibitors and stimulated with fMLP 
(1 µM). Superoxide generation was evaluated with SOD inhibitable Cytochrome C 
reduction at 550nm. Results from this experiment show that BEL inhibited superoxide 
generation on a dose dependent manner (ICso; 1 0µM). At a concentration of 20µM BEL, 
there was a 100% reduction in the superoxide generation (Figure 12). However, pre-
incubation with pyrrolidine did not result in a significant inhibition of superoxide 
generation. Lower concentrations of pyrrolidine (0.1 µM, 1 µM) demonstrated a priming 
effect and increase in the superoxide generation. This increase in superoxide 
generation was not significant (Figure 12). Thus, iPLA2, but not cPLA2, is involved in 
superoxide generation in neutrophils stimulated with fMLP. 
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Figure 12. iPLA2 regulates superoxide generation in neutrophils . Neutrophils (25 x 106 /ml) 
were incubated with the inhibitors for 15 minutes at 37 ° C and then washed once with PBS to 
remove the chemicals. Neutrophils were then resuspended in PBS and incubated at room 
temperature for a period of 15 minutes. Cells were then stimulated with 1 µM fMLP and 
superoxide generation was evaluated using a superoxide dismutase inhibitable cytochrome C 
assay. The intensity of the colorimetric reaction was measured in a microplate reader at 550 nm. 
Data are represented as percent inhibition (%) and are expressed as mean ± SEM for 3 different 
donors . 
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cPLA2 and iPLA2 Regulate LTB4 Generation in Neutrophils 
Since the primary function of PLA2 is to catalyze the release of AA from membrane 
phospholipids and in neutrophils, AA is primarily metabolized to leukotrienes by 5-
lipoxygenase (5-LO), wherein L TB4 is the predominant isotype. To confirm the specific 
mechanism of inhibition of PLA2 by BEL and pyrrolidine, we have investigated their role 
was investigated in the AA pathway, specifically in the inhibition of L TB4 generation. 
Calcium ionophore A23187 was utilized to induce the release of L TB4 from neutrophils. 
When neutrophils are treated with A23187, there is a rapid calcium mobilization within 
the cell from intracellular calcium stores. The released calcium activates calcium 
dependent PLA2s and lipoxygenases. The results from these experiments demonstrate 
that pyrrolidine completely blocked L TB4 generation on a dose depend~nt manner (ICso; 
0.1 nM). Pyrrolidine completely blocked L TB4 generation at 1 0µM (Figure 13). BEL did 
not inhibit L TB4 generation completely and resulted in a 65% reduction at a high dose of 
20µM. The results from this experiment suggest the specific inhibition of cPLA2 and 
iPLA2 by pyrrolidine and BEL. 
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Figure 13. cPLA2 and iPLA2 regulate L TB4 generation in neutrophils. Neutrophils (10 x 106/ 
ml) were suspended in PBS containing 0.25% BSA and 1 mM CaCl2 and stimulated with 2µM 
A23187 for 30 minutes. The reactions were stopped on ice and samples were centrifuged at 
5500 RPM for 15 minutes at 4 °C. The supernatants were collected and a competitive ELISA for 
L TB4 was performed. Data are presented as percent inhibition of L TB4 and are expressed as 
mean ± SEM for 3 separate donors. 
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PAP-1 does not Regulate Superoxide Generation in Neutrophils 
Studies have suggested that BEL is also a potent inhibitor of PAP-1 (133). PAP-1 
catalyzes the conversion of PA to DAG in the Kennedy pathway. Hence, if BEL 
mediated inhibition of PAP-1 results in the suppression of superoxide generation, and 
then the direct inhibition of PAP-1 will also give the same results. To investigate the role 
of PAP-1 in superoxide generation in neutrophils, propranolol hydrochloride, a specific 
inhibitor of PAP-1 was utilized. Results from this experiment suggested that propranolol 
hydrochloride (1 SOµM) did not significantly inhibit superoxide reduction in neutrophils 
compared to BEL (Figure 14) supporting that iPLA2 regulates superoxide generation in 
neutrophils. 
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Figure 14. PAP-1 does not regulate superoxide release. Neutrophils (25x106/ml) were 
incubated with BEL (20µM) and propranolol hydrochloride (150µM) for 15 minutes at 37°C. Cells 
were then washed once and resuspended in PBS and were stimulated with 1 µM fMLP. 
Superoxide release was evaluated by the reduction of cytochrome C as read at 550nM. Results 
are expressed as mean± SEM for n =3. 
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BEL does not inhibit the Phosphorylation of p47phox 
Superoxide generation in neutrophils requires the assembly of NADPH oxidase 
components. The phosphorylation and translocation of p47phox is a key event in this 
process. To investigate whether BEL inhibited the fMLP induced PKC dependent 
p47phox phosphorylation, neutrophils were stimulated with fMLP (1 µM) in the presence or 
absence of BEL (20µM) for a period of 180 seconds. In unstimulated cells p47 phox was 
not phosphorylated. Maximum phosphorylation of p47 phox was evident at 30 seconds 
with a gradual reduction at 180 seconds (Figure 15). There was no significant difference 
in the phosphorylation of p47 phox in cells treated with or without BEL at 30, 60 and 180 
seconds respectively. The data from these experiments provide further evidence that 
BEL does not inhibit superoxide generation by suppressing the phosphorylation of p47 
phox 
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Figure 15. BEL does not inhibit the phosphorylation of p47phox_ Neutrophils (25 x 106 / ml) 
were incubated with or without BEL (20µM) and then stimulated with 1 µM fMLP for of 30, 60 or 
180 seconds. The reaction was stopped by adding ice-cold lysis buffer and samples were 
prepared for western blotting . Equal amount of protein (10µg/lane) was loaded on 10% SOS-
PAGE gels . Membranes were then probed with anti PKC phospho serine substrate antibody 
(1 :500). The membranes were stripped and reprobed with anti p4/hox (1 :500). Data were 
evaluated by a densitometer and the results are presented as phospho p47phox / total p47phox ratio. 
Results are expressed as mean ± SEM for n =3. 
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BEL does not Induce Cell Apoptosis or Cell Death in Neutrophils 
BEL is a potent inducer of apoptosis in certain cell lines (133). To investigate if BEL 
was inhibiting superoxide generation in neutrophils by inducing cell death or 
apoptosis, cells treated with different concentrations of BEL were stained with CD16 
(neutrophil marker), annexin V (apoptotic marker) and propidium iodide (necrotic 
marker) by FACS analyses. BEL treated cells were also counted in a 
hemocytometer by a trypan blue exclusion method. Cells taking up trypan blue dye 
were considered as dead or dying cells. Results also show that BEL treated cells (1, 
5, 10, 15 and 20 µM) did not induce significant cell death compared to vehicle control 
(Figure 16 B). FACS analysis with CD16 staining confirmed that more than 95% of 
cells isolated were neutrophils (Figure 16A). Cells treated with different 
concentrations of BEL, (1, 5, 10, 15 and 20µM) did not show any significant necrosis 
or apoptosis when compared to vehicle control 0.1 % DMSO and PBS. Only 5% cells 
treated with 1 µM staurosporine (positive control) were apoptotic and necrotic (Figure 
16 C). The data from these experiments suggests that 15 minutes of incubation with 
different doses of BEL is insufficient to induce death in neutrophils. 
55 
A.) 
B.) 
CD16 
V o----------. 
(') 
o-
t!1~ -· 
..-0• ;: . · . .. , . ' 
- ' ........ ; •. ·-
;, , __ ,. : ,.~ 
00 ~~_;:: -.·/-' 
- 0 200 ~00 500 800 
FSC-H 
10
1
00 
CD16 
0 
~ 
0 
N 
.... 
0 
i; O'> 
C 
::::,: 
00 
U.o 
0 
("') 
0 
10° 
Trypan Blue exclusion 
120 
0) 100 
.0 
m 80 
.> 
U'J 60 
0) 
0 40 
~ 20 
0 
BEL 0 1 5 10 15 20 
(1,.1M) 
56 
C.) 
v
0
~ PBS <"> • 
'= . 
~o · . •. 
_, -
..._ 
0 
= c :~o- .n n nJ n41 
~~tJ10pMBEL 
r~ . 
et 
o _ I~ 
0
10 10 I O;i 104 
. 151,1M BEL 
-B··-· ~ . ~ ,.., 0 C . 
a; 1~ . ·,o 10 10 104 
FLI~ 
20 pM BEL 
104 
Annexln V 
Annexin V 
c:> 
(',,I 
If> 
~ 
:cc::, 
~~ 
u 
In 
103 10.q 
~ Nane Paraneler- Gale 
■ PBS FU -ff G2 0.1~()11S0 A.1..ff G2 
11MBB... A.1..ff G2 
5-MEIEL A.1..ff G2 
1._.IEL A.1..ff G2 
l~IEL FL1-H G2 
~IEL FL1-H G2 
11MSTS A.1..ff G2 
Figure 16. BEL does not stimulate apoptosis in neutrophils. Neutrophils (1Qx1Q6 / ml) were 
incubated with or without BEL (1 µM-20µM) for 15 minutes at 37° C. Cells were stained with A.) 
CD16 to identify neutrophils B.) Trypan blue to assess viability and C.) Labeled with Annexin V or 
Propidium Iodide to detect apoptotic and necrotic neutrophils. The upper right (UR) quadrant of 
the dot blot data represents Annexin V and Propidium iodide positive cells. The histogram 
represents Annexin V positive cells at a threshold setting of 102 FL 1-H. 
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iPLA2 Knockdown Inhibits Superoxide Production in Neutrophils 
Human neutrophils pose many disadvantages, such as their inability to be cultured 
for long periods and their intolerance to transfection. Hence, we used a HL60 cell 
line to assess the role of iPLA2 in superoxide generation. HL60 cells were 
differentiated with 1.25% DMSO for six days to convert them into neutrophil like cells. 
After three days cells were transfected with si-iPLA2 using Amaxa Nucleofector 
device. This technique utilizes electroporation to create micropores in the cell 
membranes. The transfected reagents were GFP, si-non-targeting (si-NT), si-
GAPDH and si-iPLA2. The cells were further incubated for three days. Uptake of GFP 
indicated that approximately 25% cells were transfected (Figure 17 A). We 
investigated the action of siRNA knockdown directed towards a housekeeping gene, 
GAPDH. GAPDH mRNA was completely knocked down and ~50% GAPDH protein 
reduction was seen. We also investigated if the transfection procedure affected the 
p4lhox protein levels. There was no change in the p47phox protein levels (Figure 
148). Transfection with siRNA towards iPLA2 resulted in ~50% reduction in mRNA 
levels and 20% reduction of protein levels for iPLA2 (Figure 17C). This knockdown 
resulted in 30% inhibition of fMLP stimulated superoxide generation (Figure 17D). 
The data from iPLA2 knockdown experiments confirm the chemical inhibition results 
that iPLA2 is the key PLA2 isoform involved in the superoxide generation from 
neutrophils. 
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Figure 17. HL60 neutrophils like cells transfected with siRNA to iPLA2 showed reduction 
in superoxide levels compared to non targeting control siRNA. A.) HL60 undifferentiated 
and differentiated neutrophil like cells were transfected with nucleofector on day 3 with 1 µM GFP 
and analyzed under fluorescent microscopy to estimate the transfection efficiency . B.) Cells were 
transfected with 1 µM si-GAPDH and non-targeting siRNA. After 72 hours samples were collected 
for quantitative real time PCR and western blotting. C.) Cells were transfected with 1 µM si-iPLA2 
and non-targeting siRNA. After 72 hours samples were collected for quantitative real time PCR 
and western blotting. D.) Cells transfected with si-iPLA2 and non-targeting siRNA were counted 
and resuspended in PBS at a concentration of 25 x 106 / ml and stimulated with 1 µM fMLP. 
Cytochrome C reduction was read in a spectrophotometer at 550nm. Data are presented as 
percent change of control and expressed as mean ± SEM for n =2, p<0.05, (student's t test). 
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Superoxide Generation Mediated by iPLA2 is Increased in Neutrophils from 
Diabetic Subjects 
Findings from figure 12 implicate iPLA2 in superoxide generation; therefore, the role of 
the iPLA2 in neutrophils from diabetic subjects was investigated. Neutrophils from poorly 
controlled glycemic subjects demonstrated a significantly increased superoxide 
generation compared to healthy controls (Figure 18A). This suggests a role of the 
glycemic control in neutrophil priming (54-56). BEL completely blocked superoxide 
generation in neutrophils from healthy and diabetic subjects (Figure 188). This suggests 
that the involvement of iPLA2 in superoxide generation is similar in healthy and diabetic 
subjects. 
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Figure 18. Neutrophils from poorly controlled diabetic subjects generate significantly 
increased superoxide compared to healthy controls and this is regulated by iPLA2• 
A) Neutrophils (25 x 106 / ml) isolated from healthy and diabetic subjects were resuspended in 
PBS and incubated at room temperature for a period of 15 minutes. Cells were then stimulated 
with 1 µM fMLP and superoxide generation was evaluated using a superoxide dismutase 
inhibitable cytochrome C assay. The intensity of the colorimetric reaction was measured in a 
microplate reader at 550 nm. B.) Neutrophils (25 x 106 / ml) from healthy and diabetic subjects 
were incubated with the inhibitors for 15 minutes at 37 ° C and then washed once with PBS to 
remove the chemicals. Neutrophils were then resuspended in PBS and incubated at room 
temperature for a period of 15 minutes. Cells were then stimulated with 1 µM fMLP and 
superoxide generation was evaluated . Data is expressed as mean ± SEM. n = 6, p < 0.05 
(ANOVA one-way with LSD post-hoc correction). 
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iPLA2 Activity is Increased in Neutrophils from Diabetic Subjects 
To investigate whether increased superoxide generation in neutrophils from diabetic 
subjects is due to an increased iPLA2 activity, modified iPLA2 assay method was utilized. 
In this method, the buffers and the substrate (Arachidonyl Thio-Phosphatidyl Choline) 
were prepared in calcium free conditions and EDTA was added as the chelating agent. 
iPLA2 has shown to be activated under calcium free conditions(113) . The results from 
these experiments show that the neutrophil cytoplasmic membrane basal PLA2 activity is 
significantly increased in the presence of EDTA (Figure 19A) compared to calcium. 
These findings suggest that the membrane bound basal PLA2 activity is calcium 
independent and confirms the involvement of iPLA2. The next experiment was 
undertaken in the presence of EDTA and without calcium to specifically investigate the 
iPLA2 activity from the membrane fractions of neutrophils from healthy and diabetic 
subjects. The membrane bound iPLA2 activity is significantly increased in neutrophils 
from diabetic subjects compared to healthy controls (Figure 198). The increased iPLA2 
activity in diabetes might be, at least, in part responsible for the increased superoxide 
generation. 
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Figure 19. Calcium independent PLA2 activity is increased in membrane fractions of 
neutrophils from diabetic subjects. A) Neutrophils (4x108/ml) were sonicated in a 
homogenization buffer supplemented with protease inhibitor. Cells were then fractionated to 
isolate the membrane components. The reaction was initiated by the addition of sample to the 
substrate Arachidonyl Thio-Phosphatidyl Choline. The reactions were stopped by the addition of 
DTNB/EGTA and the plate was read at 415nm. The buffers for this assay were calcium free and 
consisted of EDTA to chelate all the surrounding calcium, thus activating calcium independent 
PLA2. Results are expressed as mean ± SEM for n=3. B.) The membrane fractions of 
neutrophils from diabetic subjects demonstrated a significant increase of calcium independent 
PLA2 activity. Data represent percent increase of iPLA2 activity over healthy controls and are 
expressed as mean ± SEM for n= 4, p < 0.05 (Student's t test) 
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iPLA2 Expression is Increased in Neutrophils from Diabetic Subjects 
Superoxide generation is increased in neutrophils from diabetic subjects and this is 
mediated by an increase in iPLA2 activity. To investigate whether this was due to an 
increased expression of iPLA2 in diabetic subjects quantitative real time PCR and 
Western blotting experiments were undertaken. The data from PCR shows that 
neutrophils from poorly controlled diabetic subjects (> 8Hb1Ac %) had a 1.4 fold change 
of mRNA of iPLA2 compared to healthy controls, however, this difference was not 
significantly different (Figure 20A). To confirm the fractionation method for Western 
blotting experiments Na+/ K+-ATPase was used as a cytoplasmic membrane marker. 
The result from this experiment shows that Na+/ K+ -A TPase is exclusively seen in the 
cytoplasmic membrane fractions (Figure 208). Western blotting data shows that iPLA2 
was exclusively expressed in the membrane fraction of the neutrophils (Figure 20C). 
Neutrophils from diabetic subjects showed a significantly increased expression of 
membrane bound iPLA2 compared to healthy controls (Figure 20D). These experiments 
suggest that increased superoxide generation in diabetes can be attributed to increased 
expression of iPLA2 at mRNA and the protein level. 
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Figure 20. iPLA2 mRNA and protein is increased in neutrophils from diabetic subjects. 
A.)Total RNA was extracted from the resting neutrophils from healthy and diabetic subjects and 
1 µg of RNA was used to prepare cDNA using RT-PCR. Approximately 1 00ng of cDNA was used 
for quantitative real time PCR using probes for actin and iPLA2 were used to estimate the fold 
change of iPLA2 normalized to actin. B.) Neutrophils (25 x 106 / ml) were rapidly lysed in 
hypertonic lysis buffer and were sonicated in ice cold water bath. An aliquot of this lysate was 
considered as whole cell lysate. The cell lysates were then centrifuged at 1,000xg for 5 minutes 
to remove all the pelleted debris and nuclear fraction. The supernatant was further centrifuged at 
11,000xg for 30 minutes to separate the cytosolic and the pelleted membrane. The membrane 
fraction was further sonicated and incubated. Ten micrograms protein/lane was loaded on a 10% 
SOS-PAGE gels. The proteins on the gels were transferred on to a PVDF membrane and the 
membranes were probed with antibody to Na+/K+ ATPase antibody (1:1000 dilution). The same 
membranes were stripped and reprobed with actin antibody (1 :2000 dilution). The levels of actin 
were evaluated as loading control. iPLA2 was quantified by densitometry and normalized to actin. 
C.) Twenty micrograms of membrane fractions of neutrophils was loaded on to 10% SOS-PAGE 
gel and transferred to a PVDF membrane. The membranes were probed overnight with iPLA2 
antibody (in 3% skim milk). D.) Membrane fractions of neutrophils from healthy and diabetic 
subjects were evaluated for the expression of iPLA2 by western blotting. The levels of actin were 
evaluated as loading control. iPLA2 was quantified by densitometry and normalized to actin. 
Results are expressed as mean ± SEM. n = 5, p < 0.05 (Student's t test) 
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Hyperglycemia Mediated Increase in Superoxide Generation is Mediated by iPLA2 
To understand the mechanism of increased superoxide generation and the role of iPLA2 
in diabetes, HL60-neutrophil like cells were used for in vitro hyperglycemia experiments. 
Since human neutrophils cannot be cultured for longer periods owing to their short life 
periods in vitro hyperglycemia experiments were carried out on the HL60-neutrophil like 
cells. For these experiments, HL60 cells were differentiated into neutrophil like cells 
over a period of six days and were then cultured for 24 hours with normal glucose (NG; 
5.SmM), high glucose (HG; 25mM), RAGE ligand (S1008; Sµg/ml), RAGE ligand and 
high glucose (S1 00B+HG) and Mannitol (MANN; 25mM). Mannitol group served as an 
osmotic control for the hyperglycemia experiments. The superoxide generation from 
these experimental groups shows that compared to NG alone, S1008 (p<0.01) and 
S100B+HG (p<0.001) demonstrate a significantly increased superoxide generation 
(Figure 21 ). The mannitol group, which was used as an osmotic control also 
demonstrated significantly increased superoxide generation compared to NG alone, but 
not HG. HG alone did not significantly increase the superoxide generation, but the 
combination group of HG with S 1008 demonstrated a significantly increased superoxide 
generation compared to HG (p < 0.001 ). This demonstrates the priming effect of high 
concentrations of glucose and AGE in superoxide generation. These results suggest 
that the increase in superoxide generation from MANN group can be attributed to an 
osmotic effect, however the receptor mediated event by S 1008 and S 1 00B+HG was 
more robust in these experiments. When BEL was added to the above mentioned 
conditions, there was a significant reduction in the superoxide generation in all groups 
suggesting that the increase in superoxide generation is mediated by iPLA2 (Figure 21). 
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Figure 21. Neutrophils cultured in hyperglycemia generate significantly increased 
superoxide which is mediated by iPLA2. Neutrophils (25 x 106 / ml) were cultured for 24 hours 
in normal glucose (NG; 5.5mM), high glucose (HG;25mM) , RAGE ligand (S100B ;5µg/ml) , RAGE 
ligand and high glucose (S100B+HG) and Mannitol (MANN ;25mM) as an osmotic control. The 
cells were counted and washed once in PBS. The cells were then incubated with or without BEL 
(20µM) for 15 minutes at 37 ° C and were washed once with PBS. The cells were stimulated with 
1 µM fMLP and superoxide release was evaluated by the reduction of cytochrome C read at 
550nm. Results are expressed as mean ± SEM for n = 3. * p < 0.05, compared to NG with fMLP , 
** p < 0.005 , compared to NG,HG and S100B with fMLP , # p < 0.05, compared to fMLP 
stimulation , ## p < 0.01 , compared to fMLP stimulation (ANOVA one-way with LSD post-hoc 
correction) . 
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Discussion 
Hyperglycemia mediated priming of neutrophils results in an enhanced oxidative burst in 
diabetes mellitus. Neutrophil NADPH oxidase mediates superoxide release and PLA2 
derived arachidonic acid is required for the activation of the assembled NADPH oxidase. 
Since PLA2 mediates the activation of NADPH oxidase, this study hypothesized that 
PLA2 is also involved in the priming of neutrophils in superoxide generation from diabetic 
subjects. The investigations carried out in Aim 1 characterized the PLA2 isoforms 
involved in the generation of superoxide in neutrophils. To evaluate the role of specific 
PLA2 isoforms involved specific chemical inhibitors were used. Results from chemical 
inhibition experiments suggested that iPLA2 but not cPLA2 was involved in the 
superoxide generation from fMLP-stimulated neutrophils. These results were interpreted 
on the basis of percentage inhibition (Figure 12) of superoxide by BEL and pyrrolidine-1 
which are the inhibitors for iPLA2 and cPLA2 respectively. The data shows that BEL 
completely inhibited superoxide whereas pyrrolidine-1 did not inhibit this process. 
Previously, it was shown that BEL at a concentration of 10 µM significantly inhibited 
superoxide generation in neutrophils stimulated with Aroclor 1242 (123). Aroclor 1242, a 
mixture of polychlorinated biphenyl directly activates iPLA2 in neutrophils towards AA 
and superoxide generation(123). However, BEL at a concentration of 100nM did not 
inhibit superoxide generation in neutrophils stimulated with fMLP (134). Thus, BEL is 
effective only at higher concentrations in the range of 1 OµM for inhibition of superoxide 
generation in neutrophils. Experiments with pyrrolidine-1 are similar to findings from 
previous studies where the inhibitor and cPLA2 null mice show the non-involvement of 
cPLA2 in superoxide generation in neutrophils (85). In order to confirm the specificity of 
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BEL and pyrrolidine-1 in the inhibition of iPLA2 and cPLA2, we examined their role in 
LTB4 generation. In neutrophils, LTB4 generation is a classical outcome of PLA2 
mediated AA mobilization pathways. It was found that in neutrophils stimulated with 
2µM A23187, the release of LTB4 was completely blocked by Pyrrolidine-1 and partially 
by BEL (Figure 13). These findings are in agreement with a study which showed that 
arachidonyl trifluoromethyl ketone (AACOCF3), a specific cPLA2 inhibitor blocked L TB4 
generation in neutrophils stimulated with A23187 (135). Another study also has shown 
that BEL blocked magnolol induced L TB4 secretion in neutrophils (136). It has been 
speculated that different pools of AA exist which serve different functions, in case of 
iPLA2 this AA is directed towards superoxide generation and in cPLA2 the AA is primarily 
routed towards eicosanoid generation (123). However, there is a need for direct 
examination to answer this speculation. 
Since aim 1 was to investigate the role of PLA2 in superoxide pathway and it was found 
that iPLA2 was involved in this process using BEL as a specific chemical inhibitor. BEL 
has been a controversial molecule since its efficacy as a specific iPLA2 inhibitor is in 
question (133). Propranolol hydrochloride, an inhibitor of PAP-1, was used to distinguish 
the effects of BEL on iPLA2 from those exerted on PAP-1, since BEL has been shown to 
potently inhibit PAP-1 (133). Figure 14 shows that PAP-1 did not inhibit superoxide 
generation, and confirms that PAP-1 is not involved in fMLP stimulated superoxide 
generation in neutrophils. Based on this experiment, it was concluded that BEL 
abrogated superoxide generation by inhibiting iPLA2 and inhibition of PAP-1 was not 
responsible for this mechanism. Superoxide generation in neutrophils requires the 
assembly of NADPH oxidase components. The phosphorylation and translocation of 
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p47phox induced by PKC is a key pathway in this event (54). To investigate whether BEL 
abrogated fMLP stimulated superoxide generation by non-specifically inhibiting PKC 
dependent p47phox phosphorylation, western blotting experiment was carried out. 
Results show that there was no significant difference in the phosphorylation of p47 phox in 
cells treated with or without BEL at 30, 60 and 180 seconds respectively (Figure 15). 
These data provide further evidence that BEL inhibits superoxide generation by 
suppressing iPLA2 activity and not inhibiting PKC activity by inhibiting p47phox 
phosphorylation. BEL is a potent inducer of apoptosis in certain cell lines (133). To 
investigate if BEL was inhibiting superoxide generation in neutrophils by inducing cell 
death apoptotic assays were performed. The results from these experiments suggested 
that 15 minutes of incubation with different doses of BEL (1, 5, 10, 15 and 20µM) is 
insufficient to induce death in neutrophils and thus inhibit superoxide generation in these 
cells (Figure 16C). The results of this experiment are consistent with other studies that 
BEL up to a dose of 20µM and lower does not induce cell death in LNCaP (human 
prostate cancer) cells (137). Finally, to confirm our data with BEL, we investigated if 
iPLA2 knockdown would inhibit superoxide generation. Figure 17D shows that silencing 
iPLA2 resulted in a 30% reduction in superoxide generation in HL-60 neutrophil like cells. 
This data is consistent with other studies which show similar results when iPLA2 is 
silenced with regards to AA mobilization, PG production, differentiation and prevention of 
death (78) (93) (138, 139). Even though there was a significant reduction in the mRNA 
levels of iPLA2 during this procedure, there was no significant reduction at the protein 
levels when compared to the si-non-targeting group. Because of the co-existence of 
various iPLA2 splice variants, the regulation can be explained by multiple mechanisms in 
different cell types and under various stimuli (78, 88, 89). Proposed explanations for a 
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low protein knockdown efficiency include that one some of the intact spliced variants 
might be providing a compensating mechanism in the absence of the main variants. 
This also might be the reason why there was only a 30% reduction in the superoxide 
levels; some of the intact spliced variants might be providing a compensating 
mechanism in the absence of the main variants. Transfection of the human iPLA2 cDNA 
into COS cells resulted in a substantial increase in calcium-independent PLA2 activity in 
cell lysate(98). However, co-transfection of the ankyrin-iPLAr1 and the iPLA2 cDNA 
resulted in a 2-fold reduction in activity compared with iPLA2 alone. This study 
suggested that the ankyrin-iPLA2 sequence can function as a negative regulator of iPLA2 
activity and that the alternative splicing of the iPLA2 gene can have a direct effect on the 
attenuation of enzyme activity (98). Another study examining glucose and oxygen 
deprivation (OGD) in mouse C2C 12 myotubes showed that iPLArVIA activation may be 
modulated by changes in the levels of active and inactive iPLArVIA isoforms (140). 
Much of the earlier work on iPLA2 was based on chemical inhibitors like MAFP and BEL. 
iPLA2 VI-A is inhibited by hydrophobic serine reactive inhibitors such as bromoenol 
lactone (BEL) (78). BEL also has various non-specific interactions when applied to living 
cells, hence it was suggested to interpret the results obtained with BEL with caution (89, 
97). BEL is also known to inhibit chymotrypsin and other serine proteases (141 ), Mg2+ 
dependent phosphatidate phosphohydrolase (PAP-1) (133), anandamide hydrolase 
(142) and notably, iPLArVIB (143). Propranolol hydrochloride (150 µM) has been used 
to distinguish the effects of BEL on iPLArVIA from those exerted on PAP-1. If a given 
process is inhibited by BEL but not by high concentrations of propranolol concentrations 
the involvement of PAP-1 can be ruled out (133). Chemical inhibitors lack specificity and 
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the use of more selective inhibition by antisense oligonucleotides or small interference 
RNA have been utilized to provide with a better understanding to the role of iPLA2. 
iPLA2 VI-A inhibition by antisense oligonucleotides reduces AA mobilization and PGs 
production in zymosan stimulated P3880 1 macrophages and inhibited monocyte 
migration to MCP-1 (78) (93). Small interfering RNA knockdown of iPLA2 inhibited the 
hormone-induced differentiation of 3T3-L 1 preadipocytes and inhibited nuclear shrinkage 
in caspase independent cell death (138, 139). Mice not expressing iPLA2 (iPLA2 
knockout mice) produced spermatozoa with impaired motility, greatly reduced fertility 
(144) and showed abnormalities in osteoblast function and BMSC differentiation (145). 
Aim 1 served to confirm the role of iPLA2 in superoxide generation in neutrophils, and in 
Aim 2, this concept of iPLA2 regulation of superoxide generation was evaluated in 
neutrophils from diabetic subjects. It was shown previously that neutrophils from poorly 
controlled diabetic subjects generate a significant amounts of superoxide compared to 
healthy controls (54, 55). Figure 18A shows that this data is consistent with the findings 
from previous studies. Neutrophils from poorly controlled diabetic subjects exhibit 
increased PKC activity, diglyceride formation and p47phox phosphorylation (55) . Also it 
has been shown that in these neutrophils there is a premature translocation of p47phox to 
the membranes, which was also consistent with the findings from in vitro hyperglycemia 
experiments (54). It was also observed in a diabetic Akita mice model, where in the 
insulin gene is disrupted and results in consistently high levels of glycemic state, there 
was an increased superoxide and a premature translocation of p47phox to the 
membranes (56). These findings strongly support the concept of a primed neutrophil 
phenotype in poorly controlled diabetes resulting in an increased superoxide generation 
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and an enhanced oxidative stress. Figure.1 BB shows that when diabetic neutrophils 
were treated with BEL (20µM), there was a complete reduction in the superoxide 
generation and this trend was similar to the data from healthy neutrophils. These 
findings support the fact that iPLA2 regulation of superoxide generation in neutrophils 
also applied to the diabetic state. This is the first study to demonstrate the role of 
iPLA2 in neutrophils from diabetic subjects. 
Oxidative stress is an imbalance between the levels of cellular oxidants and antioxidants 
which can result in tissue injury and dysfunction. Specifically, there is an increase in the 
levels of oxidants like superoxide, hydrogen peroxide and hypochlorous acid and 
reduction in the levels of antioxidants like glutathione, vitamin E, ascorbic acid, 
glutathione peroxidase, superoxide dismutase and catalase (33). It has been shown that 
oxidative stress is increased in diabetes and neutrophils have been identified to play a 
major role in superoxide generation in hyperglycemia (54-56). However, it is not clear if 
this increase in superoxide in primed neutrophils is due to a concomitant decrease in the 
level of antioxidants like glutathione and superoxide dismutase. Therefore, it would be 
of further interest to investigate the role of antioxidants in neutrophils in diabetes. 
Because hyperglycemia primes neutrophils for an enhanced superoxide generation and 
iPLA2 regulates this process we wanted to investigate whether increased iPLA2 activity 
was involved in this priming. To detect the activity of iPLA2 and not cPLA2, a kit originally 
designed for cPLA2 but modified to only detect iPLA2 activity was used. iPLA2 activity 
was assessed and is enhanced by depleting calcium levels (122). The results from 
Figure 19A shows that when neutrophil membrane fractions were treated with or without 
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calcium, the calcium-depleted group shows a significant increase in basal PLA2 activity 
compared to the lysates treated with calcium. This suggests that the predominant PLA2 
activity from neutrophil membrane fractions is calcium independent, hence this reflects 
iPLA2 activity. The results are in agreement with data from a study, which showed that 
iPLA2 activity was increased in the presence of 8APTA-AM or thapsiagrin (calcium 
chelators) (122). Another PLA2 isoform has been shown to exhibit similar calcium 
independent activity (146). This study reported the presence of a novel 60.9 kDa 
membrane bound calcium independent cPLA2-'Y, also known as group cPLAr IVC. The 
sequence encodes a 541-amino acid protein containing a domain with significant 
homology to the catalytic domain of the 85-kDa cPLA2 (cPLAr cx.). cPLAr 'Y does not 
contain the regulatory calcium-dependent lipid binding (Cal8) domain found in cPLA2JI . 
However, cPLAr Y does contain two consensus motifs for lipid modification, a prenylation 
motif ( - CCLA) at the C terminus and a myristoylation site at the N terminus. 
Interestingly, cPLAr 'Y demonstrates a preference for arachidonic acid at the sn-2 
position of phosphatidylcholine as compared with palmitic acid. cPLAr l encodes a 3-
kilobase message, which is highly expressed in heart and skeletal muscle, suggesting a 
specific role in these tissues. Identification of cPLAr Y reveals a newly defined family of 
phospholipases A2 with homology to cPLA2 (146). It would of interest to identify this 
isoform in neutrophil membranes and differentiate its activity from iPLA2. 
iPLA2 activity is significantly increased in neutrophils from diabetic subjects (Figure 198). 
We also report that an increase in superoxide generation in neutrophils from diabetic 
subjects is because of an increase in iPLA2 activity and this is because of an increase in 
the expression of iPLA2 at the message (Figure 20A) and protein level (Figure 208). 
Thus, these findings attribute an increased activity of iPLA2 to inflammation in diabetes. 
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It was shown that iPLA2 drives the onset of an acute pleurisy induced inflammation 
model in male Wistar rats, through the generation of PGE2, LT84, PAF, and IL-113 (147). 
During the resolution phase, there was an induction of sPLA2 (type II and V) and cPLA2. 
This study was the first to identify the specific involvement of PLA2 isoforms in the 
initiation and resolution of acute inflammation(147). The onset of the inflammation was 
characterized by the expression of iPLA2 from 2 hours until 24 hours within the 
inflammatory cells and inflammatory exudates. Injection of BEL into the animals was 
associated with significant reductions in the levels of PGE2, L T84, PAF, and IL-1 l3. 
Expression of sPLA2 (type 11 and V) after 24 hours was associated with the release of 
PAF, LxA4 which was responsible for the expression of cPLA2 and in tandem with COX-2 
pro-resolving PGD2 was synthesized (147). Since the complications of diabetes are 
associated with inflammation, it will also be of further interest to investigate if the 
increase in the activity and expression of iPLA2 in neutrophils will be associated with a 
reduction of activity and expression of cPLA2 and sPLA2. 
Arachidonic acid (AA) is necessary for the activation of 0 2- production and the 
associated H+channel-mediated efflux (74). AA can act by increasing the affinity of 
NADPH on to the oxidase, regulation of a proton channel, by facilitating the translocation 
of cytosolic components to the membrane, increasing the affinity of GTP binding sites in 
the membrane and enhancing the dissociation of rac G protein from its regulatory 
molecule, GDl(148). AA mediates priming of NADPH oxidase and enhances the 
production of superoxide generation when cells are challenged with a secondary 
stimulus like fMLP(148). Though the exact mechanism of how iPLA2 activation results in 
superoxide generation is unknown, it is plausible to think that this could take place either 
by direct interaction with the assembled NADPH oxidase components on the membrane 
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or indirectly through the generation of AA [67-71). It is necessary to ascertain whether 
iPLA2 regulates the generation of superoxide generation by the production of AA or 
direct interaction with the components of NADPH oxidase. Neutrophils pre-labeled with 
[3H]-arachidonic acid display increased [3H] arachidonate release on exposure to AGE-
albumin over exposure to albumin alone (134). AGE augmentation of the activated 
neutrophil respiratory burst required AA generation, through which neutrophil NADPH 
oxidase may be up regulated, enhancing reactive oxygen species output. However, this 
study showed that AA is generated by cPLA2 , which may be stimulated through an AGE-
activated redox-sensitive pathway (134). 
Aim 3 assesses the mechanism of neutrophil priming in diabetes utilizing an in vitro 
hyperglycemia experiment with the HL60-neutrophil cell line. Primary neutrophils are 
end-stage cells that cannot be cultured for long periods of time (>4 h) without losing 
responsiveness to various agonists or becoming apoptotic (149). The HL60 cell line has 
been extensively used to simulate neutrophil function in vitro, since they can express the 
phenotype of granulocytes upon incubation with polar solvents (129) (150, 151 ). The 
neutrophil priming seen in diabetes was reproduced in this model by using high glucose 
and RAGE ligand; S1008 (Figure 21). An overwhelming body of literature exists for the 
involvement of AGE: RAGE in diabetic complications (54, 152), hence S1008 was used 
as a RAGE ligand for in vitro hyperglycemia experiments. It was shown that S1008 
induced increase in superoxide generation was mediated by ERK 1 /2 and premature 
translocation of p4 7phox and its association with p22phox on the cytoplasmic 
membrane(54). High glucose alone did not induce any significant change, but when 
combined with S1008, there was a synergistic response which was much greater than 
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S 1008 alone with respect to superoxide generation and premature translocation of 
p47phox (54). The priming effect of S1008 and S100 + HG, which represent poor 
glycemic control in diabetes subjects, was reproduced in the in vitro hyperglycemia 
experiment (Figure 21 ). Though high glucose alone did not contribute to a significant 
superoxide generation compared to normal glucose alone, its combination with S 1008 
resulted in a pronounced superoxide generation suggesting that high glucose levels and 
AGE regulate the priming event in neutrophils. These findings suggest that receptor 
mediated interaction between AGE and RAGE was more pronounced in the priming 
event rather than high glucose alone. These findings were observed during the 24-hour 
incubation of neutrophils in hyperglycemia and represent the approximate duration of 
neutrophil circulation and subsequent exposure to glucose and AGE in the blood of a 
diabetic subject. However, it is necessary to investigate the effects of high glucose and 
S1008 for longer durations on the neutrophil iPLA2 activity and superoxide generation. In 
the presence of BEL there was a significant reduction in superoxide generation, 
suggesting that iPLA2 regulated priming response in hyperglycemia. 
The mechanism of HG and S1008 induced increased iPLA2 activity is unknown. In the 
presence of Ca2+, calmodulin binds tightly to iPLArVIA resulting in inhibition of the 
enzymatic activity. In the absence of Ca2+, calmodulin would separate from and relieve 
its tonic inhibition of iPLA2 resulting in its activation (90). It can be speculated that 
hyperglycemic conditions will create a state of Ca2+ depletion resulting in iPLA2 
activation. Studies have shown that in hyperglycemic conditions calcium influx into the 
cells is reduced. Cultured mesangial cells grown under high glucose conditions, as a 
model of the diabetic microenvironment, display reduced Ca2+ signaling in response to 
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vasoconstrictors, probably due to down regulation by elevated PKC activity. Impairment 
of Ca2+ influx via store operated calcium channels by high glucose is one mechanism of 
the reduced Ca2+ influx responsiveness to vasoconstrictors. This event is mediated by 
PKC and may contribute to the glomerular haemodynamic changes in the initial stages 
of diabetes mellitus(153). AGE-BSA reduced Ca2+ release from intracellular stores in 
mesangial cells in response to vasoconstrictors(154). AGE also inhibited store-operated 
Ca2+ influx through plasma membrane channels, assessed by addition of 1 to 10 mM 
extracellular Ca2+ to cells previously held in Ca2+ free media. These findings suggest 
that glycated macromolecules or matrix components may inhibit transmembrane Ca2+ 
signaling of glomerular cells through binding to a specific AGE receptor, thus mediating 
some of the known functional effects of HG on the kidney(154). However, it is unknown 
if neutrophils exposed to hyperglycemic conditions will also lead to an inhibition in the 
calcium influx. Another possible explanation is that RAGE ligation by S 1008 increases 
PKC activity (152) resulting in iPLA2 activation (93, 94). No phosphorylation sites have 
been identified in the iPLA2 protein; however, this discovery might help understand the 
activation and signaling involved. 
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Summary 
Enhanced superoxide generation from neutrophils in diabetes contributes to an 
increased burden of tissue oxidant stress and injury. In diabetes, neutrophils present as 
a primed phenotype due to an increase in PKC activity and premature translocation of 
p47phox on the membrane . However, little is known about the role of PLA2 in the 
activation of the NADPH oxidase. The role of iPLA2 in superoxide generation in 
neutrophils was confirmed by BEL and siRNA. The increase in superoxide generation in 
neutrophils from individuals with diabetes is in part attributed to an increase in the 
activity and expression of iPLA2. Neutrophils cultured with high glucose and S 1008 for 
24 hours showed a significant increase in superoxide generation and this was 
significantly inhibited by BEL. This dissertation identifies the novel role of iPLA2 
mediated priming in the activation of NADPH oxidase in neutrophils in diabetes (Figure 
22). 
Conclusions 
• iPLA2 and not cPLA2 regulates superoxide generation in neutrophils. 
• Neutrophils from diabetic subjects generate significantly increased superoxide 
compared to healthy controls and this is regulated by iPLA2. 
• The expression and activity of iPLA2 is significantly increased in neutrophils from 
diabetic subjects. 
• The superoxide generation from neutrophils is increased in hyperglycemic 
conditions and this is mediated by iPLA2. 
• iPLA2 inhibition will serve as a pharmacological target in controlling the 
inflammatory effects of diabetes. 
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Figure 22. iPLA2 mediates priming for an enhanced superoxide generation in neutrophils 
in diabetes. NADPH oxidase assembly results from PKC activation and phosphorylation of 
cytosolic subunits (p47phox, p67phox, p40phox and Rac-2) and translocation to membrane and 
association with gp91 and p22phox_ iPLA2 activates this complex to generate superoxide . In 
diabetes mediated hyperglycemia , there is an increase in PKC activation, premature translocation 
of p47phox to the membrane and an increase in the activity and expression of iPLA2 resulting in an 
enhanced superoxide generation . 
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